White Blood Cell News and Research

RSS

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

10 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant.

31 May 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

27 May 2010

Contaminant in cocaine impairs immune systems

Toxicologists across the country are sounding the alarm about a contaminant increasingly found in cocaine that is impairing cocaine users' immune systems, subjecting them to various infections and, in some cases, causing death.

26 May 2010

Study confirms effectiveness of CT for diagnosis of appendicitis

When CT results suggest appendicitis, but a patient's symptoms are inconsistent with the acute condition, physicians should consider a diagnosis of chronic or recurrent appendicitis and surgical treatment, according to a new study published in the online edition and July printed issue of the journal Radiology.

26 May 2010

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

Cincinnati Children's Hospital Medical Center launches REGID

A new nationwide registry will allow researchers to conduct larger, more effective studies of often misdiagnosed disorders that affect thousands of children in the United States.

19 May 2010

Protein PEA-15 stops T-cell proliferation

New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.

5 May 2010

Short-term calorie restriction improves function of T-cells

Scientists funded by the Agricultural Research Service (ARS) found that volunteers who followed a low-calorie diet or a very low-calorie diet not only lost weight, but also significantly enhanced their immune response. The study may be the first to demonstrate the interaction between calorie restriction and immune markers among humans.

30 Apr 2010

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.

24 Apr 2010

Defects in carbon nanotubes stimulate body's natural immune response: Study

Yale University engineers have found that the defects in carbon nanotubes cause T cell antigens to cluster in the blood and stimulate the body's natural immune response.

21 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

White Blood Cell News and Research

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Combination therapy appears to improve outcome of women with late-stage ovarian cancer

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Patients with transformed lymphoma show positive response to lenalidomide: Research

Contaminant in cocaine impairs immune systems

Study confirms effectiveness of CT for diagnosis of appendicitis

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Cincinnati Children's Hospital Medical Center launches REGID

Protein PEA-15 stops T-cell proliferation

Short-term calorie restriction improves function of T-cells

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Defects in carbon nanotubes stimulate body's natural immune response: Study

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

High level of microRNAs found in patients with high-risk multiple myeloma

Immunology eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News